Survival Benefit and Efficacy of Gefitinib in Recurrent/Metastatic Head and Neck Cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Survival Benefit and Efficacy of Gefitinib in Recurrent/Metastatic Head and Neck Cancer ; volume:28 ; number:03 ; year:2007 ; pages:5-10
Indian journal of medical & paediatric oncology ; 28, Heft 03 (2007), 5-10

Contributor: Rao, R. Ranga
Konnpal, Anil
Bansal, Lalit
Dhiman, Amit
Khatri, Sameer
Rawat, Shneh
Dewan, Ajay

DOI: 10.1055/s-0041-1733221

URN: urn:nbn:de:101:1-2022042811393205893961

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Rao, R. Ranga
Konnpal, Anil
Bansal, Lalit
Dhiman, Amit
Khatri, Sameer
Rawat, Shneh
Dewan, Ajay

Other Objects (12)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

$Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma$

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

$Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma$

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

$Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma$

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Survival Benefit and Efficacy of Gefitinib in Recurrent/Metastatic Head and Neck Cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Benefit of salvage total pharyngolaryngoesophagectomy for recurrent locally advanced head and neck cancer after radiotherapy

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Recurrent neck myxofibrosarcoma: a case report

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Related objects

Reset password